ClinicalTrials.gg
Active, not recruitingNCT06884293Updated May 12, 2026

A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)

A Phase 3 interventional study of IBI362 and semaglutide in Overweight and Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
479
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing mazdutide in Overweight — 7 open to participants now, 8 under way, 3 of them phase 3. mazdutide · Overweight.

Enrollment
4th of 15
479 · median 180
Started
2025
with 1 other
Phase 3
4 of 15
2 open now
Registered
9th of 15
by date
Lead sponsor
8 of 15
Innovent Biologics (Suzhou) Co. Ltd.

Among the 15 studies testing mazdutide in Overweight, this one is the 4th largest by enrollment, is one of 2 that started in 2025, is one of 4 in phase 3, and was the 9th registered.

Overweight

3,613 studies on the registry are indexed under Overweight; 861 are open to participants now.

Browse Overweight studies →

Open to participants now

7 of the 15 studies testing mazdutide in Overweight are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

About mazdutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 534 Overweight studies recruiting now, 159 (30%) set no upper age limit and 347 (65%) stop at 75 or younger; 64 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing mazdutide in Overweight, or all of them as a file.
02

Study summary

This is a multicenter, randomized, open-label Phase 3 clinical study comparing the efficacy and safety of IBI362 9 mg QW versus Semaglutide 2.4 mg QW in overweight or obese (BMI≥27kg/m2) MAFLD subjects. Subjects will be randomly assigned to IBI362 9 mg and Semaglutide 2.4 mg groups. All study treatment will be administered once-weekly and subcutaneously. The entire trial cycle includes a 4-week screening period, a 48-week open-label treatment period, and a 12-week drug withdrawal safety follow-up period.

03

Conditions studied

  • Overweight
  • Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age 18 years or older at the time of signing
  2. diagnosed as MAFLD according to the Chinese Guideline for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)
  3. liver fat content ≥8% measured by MRI-PDFF
  4. ≥27 kg/m2
  5. Weight change ≤5% within 3 months before screening
  6. ≤10%

Exclusion criteria

Exclusion Criteria:

  1. Subjects who the investigator thinks may be allergic to the components in the study drug or similar drugs
  2. Used drugs or alternative therapies with weight loss effects within 3 months before screening, including but not limited to: GLP-1 receptor agonists, orlistat, phenylpropanolamine, chlorpheniramine, phentermine etc.
  3. Received chronic (>2 weeks) systemic treatment within 3 months before screening (excluding topical, intraocular, intranasal, and inhaled administration)
  4. Previous diagnosis of type 1 diabetes (including adult latent diabetes)
  5. Active or untreated malignant tumors within 5 years before screening, or patients are in remission of clinical malignant tumors (except patients with skin basal cell carcinoma and squamous cell carcinoma, cervical carcinoma in situ, prostate carcinoma in situ or papillary thyroid carcinoma who have no recurrence after surgery)
  6. Mental illness existed in the past or at the time of screening, and the researcher thinks it is not suitable to participate in this study
  7. Pregnant or lactating women, or men or women who are fertile and unwilling to use throughout the study period
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
479 participants (actual)

Study arms

  • Active comparator
    Semaglutide

    Drug: semaglutide

  • Experimental
    IBI362

    Drug: IBI362

Interventions

  • DrugIBI362

    Once-weekly injections of gradually increased doses of IBI362, subcutaneously (SC): starting dose is 2.0 mg, after 4 weeks of administration, increase to 4.0 mg; After another 4 weeks, increase to 6mg; After another 4 weeks, increase to the maximum dose 9mg for 36 weeks

  • Once-weekly injections of gradually increased doses, subcutaneously (SC): starting dose is 0.25 mg, after 4 weeks of administration, increase to 0.5 mg; After another 4 weeks, increase to 1mg; After another 4 weeks, increase to 1.7mg; After another 4 weeks, increase to the maximum 2.5mg for 32 weeks

06

What researchers measure

Primary outcomes

  1. percentage change in body weight from baseline

    Time frame: at Week 48

  2. percentage change in liver fat content from baseline measured by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF)

    Time frame: at Week 48

Secondary outcomes

  1. percentage change in liver fat content from baseline measured by MRI-PDFF

    Time frame: at Week 8, 16, and 24

  2. Absolute value change in liver fat content from baseline measured by MRI-PDFF

    Time frame: at Week 8, 16, 24, and 48

  3. Proportion of subjects with weight loss >10% from baseline and liver fat content <5%

    Time frame: at week 48

  4. percentage change in body weight from baseline

    Time frame: at week 24

  5. Changes in systolic blood pressure and diastolic blood pressure from baseline

    Time frame: at week 48

  6. percentage changes in total cholesterol,triglyceride (TG), non-High Density Lipoprotein Cholesterol (non-HDL-C), Low Density Lipoprotein Cholesterol (LDL-C), HDL-C (High Density Lipoprotein Cholesterol) from baseline

    Time frame: at week 48

  7. Changes in serum uric acid from baseline

    Time frame: at week 48

  8. Changes in hemoglobin A1c (HbA1c) from baseline

    Time frame: at week 48

  9. Changes in Homeostasis Model Assessment 2-B (HOMA2-B) from baseline

    Time frame: at week 48

  10. Changes in Homeostasis Model Assessment 2-IR (HOMA2-IR) from baseline

    Time frame: at week 48

  11. Changes of scores in 36-item Short-Form Health Survey version 2(SF-36v2) questionnaire from baseline

    Using norm-based scoring (NBS),each subscale has a different maximum and minimum score, with higher scores reflecting better levels of functioning

    Time frame: at week 48

  12. Changes of scores in The Impact of Weight on Quality of Life-Lite Clinical Trials Version(IWQoL-Lite-CT) questionnaire from baseline

    Total score ranging from 0 to 100, with higher scores reflecting better levels of functioning

    Time frame: at week 48

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.

Of 127 industry-sponsored phase 3 interventional studies under Overweight, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 27. This study's planned 19 months is close to that.

Counting every sponsor, half of 136 studies reached it within 21 months; a quarter within 17 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2025
First posted
Mar 19, 2025
StartActual
May 9, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06884293
Responsible party
Sponsor
First posted
Mar 19, 2025
Start date
May 9, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
May 12, 2026

Study contacts

Lixin Guo, M.D
principal investigator · Beijing Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mazdutide

Start the discussion